{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:53:20Z","timestamp":1793656400566,"version":"4.5.1"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82404015, 22077059, 22277048, 92253304"],"award-info":[{"award-number":["82404015, 22077059, 22277048, 92253304"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82404015, 22077059, 22277048, 92253304"],"award-info":[{"award-number":["82404015, 22077059, 22277048, 92253304"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shenzhen Medical Research Funding","award":["A2303067"],"award-info":[{"award-number":["A2303067"]}]},{"name":"Shenzhen Innovation of Science and Technology Commission Grants","award":["JCYJ20240813100059001, RCYX20210609103118010, QTD20221101093558015"],"award-info":[{"award-number":["JCYJ20240813100059001, RCYX20210609103118010, QTD20221101093558015"]}]},{"name":"Shenzhen Innovation of Science and Technology Commission Grants","award":["JCYJ20240813100059001, RCYX20210609103118010, QTD20221101093558015"],"award-info":[{"award-number":["JCYJ20240813100059001, RCYX20210609103118010, QTD20221101093558015"]}]},{"DOI":"10.13039\/501100010226","name":"Guangdong Provincial Department of Education","doi-asserted-by":"crossref","award":["2024KQNCX052"],"award-info":[{"award-number":["2024KQNCX052"]}],"id":[{"id":"10.13039\/501100010226","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02364-0","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T18:45:35Z","timestamp":1758739535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Evolution of direct RAS inhibitors: from undruggable target to clinical breakthroughs"],"prefix":"10.1186","volume":"24","author":[{"given":"Xia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aotian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"issue":"1","key":"2364_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11\u201322.","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"2364_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar SR, Velcheti V, Neel BG, Wong KK. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19(10):637\u201355.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"2364_CR3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11(11):761\u201374.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2364_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1128\/MMBR.00031-10","volume":"75","author":"M Cargnello","year":"2011","unstructured":"Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev. 2011;75(1):50\u201383.","journal-title":"Microbiol Mol Biol Rev"},{"key":"2364_CR5","doi-asserted-by":"crossref","unstructured":"Hymowitz SG, Malek S. Targeting the MAPK Pathway in RAS Mutant Cancers. Cold Spring Harb Perspect Med. 2018;8(11):a031492.","DOI":"10.1101\/cshperspect.a031492"},{"key":"2364_CR6","doi-asserted-by":"crossref","unstructured":"Nimnual, A.; Bar-Sagi, D., The two hats of SOS. Sci STKE. 2002, 2002 (145), pe36.","DOI":"10.1126\/scisignal.1452002pe36"},{"issue":"1","key":"2364_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu DK, Nissley DV, McCormick F. RAS Proteins and Their Regulators in Human Disease. Cell. 2017;170(1):17\u201333.","journal-title":"Cell"},{"issue":"7","key":"2364_CR8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1242\/jcs.182873","volume":"129","author":"GA Hobbs","year":"2016","unstructured":"Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129(7):1287\u201392.","journal-title":"J Cell Sci"},{"issue":"15","key":"2364_CR9","doi-asserted-by":"publisher","first-page":"4535","DOI":"10.1021\/bi962556y","volume":"36","author":"MR Ahmadian","year":"1997","unstructured":"Ahmadian MR, Hoffmann U, Goody RS, Wittinghofer A. Individual rate constants for the interaction of Ras proteins with GTPase-activating proteins determined by fluorescence spectroscopy. Biochemistry. 1997;36(15):4535\u201341.","journal-title":"Biochemistry"},{"issue":"5","key":"2364_CR10","first-page":"2050","volume":"12","author":"P Gideon","year":"1992","unstructured":"Gideon P, John J, Frech M, Lautwein A, Clark R, Scheffler JE, Wittinghofer A. Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity. Mol Cell Biol. 1992;12(5):2050\u20136.","journal-title":"Mol Cell Biol"},{"issue":"5324","key":"2364_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1126\/science.277.5324.333","volume":"277","author":"K Scheffzek","year":"1997","unstructured":"Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F, Wittinghofer A. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science. 1997;277(5324):333\u20138.","journal-title":"Science"},{"issue":"3","key":"2364_CR12","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nchembio.1435","volume":"10","author":"MJ Smith","year":"2014","unstructured":"Smith MJ, Ikura M. Integrated RAS signaling defined by parallel NMR detection of effectors and regulators. Nat Chem Biol. 2014;10(3):223\u201330.","journal-title":"Nat Chem Biol"},{"issue":"14","key":"2364_CR13","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior IA, Hood FE, Hartley JL. The Frequency of Ras Mutations in Cancer. Can Res. 2020;80(14):2969\u201374.","journal-title":"Can Res"},{"issue":"5","key":"2364_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401\u20134.","journal-title":"Cancer Discov"},{"issue":"8","key":"2364_CR15","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","author":"A. P. G.","year":"2017","unstructured":"Consortium, A. P. G. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discov. 2017;7(8):818\u201331.","journal-title":"Cancer Discov"},{"key":"2364_CR16","doi-asserted-by":"crossref","unstructured":"Lee, J. H.; Sanchez-Rivera, F. J.; He, L.; Basnet, H.; Chen, F. X.; Spina, E.; Li, L.; Torner, C.; Chan, J. E.; Yarlagadda, D. V. K.; Park, J. S.; Sussman, C.; Rudin, C. M.; Lowe, S. W.; Tammela, T.; Macias, M. J.; Koche, R. P.; Massague, J., TGF-beta and RAS jointly unmask primed enhancers to drive metastasis. Cell. 2024, 187 (22), 6182\u20136199 e29.","DOI":"10.1016\/j.cell.2024.08.014"},{"key":"2364_CR17","doi-asserted-by":"crossref","unstructured":"Mahadevan, K. K.; LeBleu, V. S.; Ramirez, E. V.; Chen, Y.; Li, B.; Sockwell, A. M.; Gagea, M.; Sugimoto, H.; Sthanam, L. K.; Tampe, D.; Zeisberg, M.; Ying, H.; Jain, A. K.; DePinho, R. A.; Maitra, A.; McAndrews, K. M.; Kalluri, R., Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8(+) T cells. Dev Cell. 2023, 58 (17), 1562\u20131577 e8.","DOI":"10.1016\/j.devcel.2023.07.025"},{"issue":"14","key":"2364_CR18","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1158\/1078-0432.CCR-09-0089","volume":"15","author":"K Schmid","year":"2009","unstructured":"Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M. EGFR\/KRAS\/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 2009;15(14):4554\u201360.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2364_CR19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ccr.2004.09.028","volume":"6","author":"A Sparmann","year":"2004","unstructured":"Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell. 2004;6(5):447\u201358.","journal-title":"Cancer Cell"},{"issue":"7477","key":"2364_CR20","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503(7477):548\u201351.","journal-title":"Nature"},{"issue":"3","key":"2364_CR21","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","volume":"6","author":"MP Patricelli","year":"2016","unstructured":"Patricelli MP, Janes MR, Li LS, Hansen R, Peters U, Kessler LV, Chen Y, Kucharski JM, Feng J, Ely T, Chen JH, Firdaus SJ, Babbar A, Ren P, Liu Y. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. Cancer Discov. 2016;6(3):316\u201329.","journal-title":"Cancer Discov"},{"issue":"7781","key":"2364_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun J-R, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O\u2019Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R, Hong DS, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217\u201323.","journal-title":"Nature"},{"key":"2364_CR23","doi-asserted-by":"crossref","unstructured":"Hallin, J.; Engstrom, L. D.; Hargis, L.; Calinisan, A.; Aranda, R.; Briere, D. M.; Sudhakar, N.; Bowcut, V.; Baer, B. R.; Ballard, J. A.; Burkard, M. R.; Fell, J. B.; Fischer, J. P.; Vigers, G. P.; Xue, Y.; Gatto, S.; Fernandez-Banet, J.; Pavlicek, A.; Velastagui, K.; Chao, R. C.; Barton, J.; Pierobon, M.; Baldelli, E.; Patricoin, E. F., 3rd; Cassidy, D. P.; Marx, M. A.; Rybkin, II; Johnson, M. L.; Ou, S. I.; Lito, P.; Papadopoulos, K. P.; Janne, P. A.; Olson, P.; Christensen, J. G., The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discov. 2020, 10 (1), 54\u201371.","DOI":"10.1158\/2159-8290.CD-19-1167"},{"issue":"8","key":"2364_CR24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","volume":"19","author":"AR Moore","year":"2020","unstructured":"Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19(8):533\u201352.","journal-title":"Nat Rev Drug Discov"},{"issue":"17","key":"2364_CR25","doi-asserted-by":"publisher","first-page":"9367","DOI":"10.1073\/pnas.97.17.9367","volume":"97","author":"DA Erlanson","year":"2000","unstructured":"Erlanson DA, Braisted AC, Raphael DR, Randal M, Stroud RM, Gordon EM, Wells JA. Site-directed ligand discovery. Proc Natl Acad Sci U S A. 2000;97(17):9367\u201372.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2364_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev.biophys.33.110502.140409","volume":"33","author":"DA Erlanson","year":"2004","unstructured":"Erlanson DA, Wells JA, Braisted AC. Tethering: fragment-based drug discovery. Annu Rev Biophys Biomol Struct. 2004;33:199\u2013223.","journal-title":"Annu Rev Biophys Biomol Struct"},{"issue":"6273","key":"2364_CR27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1126\/science.aad6204","volume":"351","author":"P Lito","year":"2016","unstructured":"Lito P, Solomon M, Li LS, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016;351(6273):604\u20138.","journal-title":"Science"},{"key":"2364_CR28","doi-asserted-by":"crossref","unstructured":"Janes, M. R.; Zhang, J.; Li, L. S.; Hansen, R.; Peters, U.; Guo, X.; Chen, Y.; Babbar, A.; Firdaus, S. J.; Darjania, L.; Feng, J.; Chen, J. H.; Li, S.; Li, S.; Long, Y. O.; Thach, C.; Liu, Y.; Zarieh, A.; Ely, T.; Kucharski, J. M.; Kessler, L. V.; Wu, T.; Yu, K.; Wang, Y.; Yao, Y.; Deng, X.; Zarrinkar, P. P.; Brehmer, D.; Dhanak, D.; Lorenzi, M. V.; Hu-Lowe, D.; Patricelli, M. P.; Ren, P.; Liu, Y., Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell 2018, 172 (3), 578\u2013589 e17.","DOI":"10.1016\/j.cell.2018.01.006"},{"issue":"7","key":"2364_CR29","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jtho.2023.03.015","volume":"18","author":"Z Li","year":"2023","unstructured":"Li Z, Song Z, Zhao Y, Wang P, Jiang L, Gong Y, Zhou J, Jian H, Dong X, Zhuang W, Cang S, Yang N, Fang J, Shi J, Lu J, Ma R, Wu P, Zhang Y, Song M, Xu C-W, Shi Z, Zhang L, Wang Y, Wang X, Zhang Y, Lu S. D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS<sup>G12C<\/sup> in Patients With NSCLC: Phase 1 Study Results. J Thorac Oncol. 2023;18(7):940\u201351.","journal-title":"J Thorac Oncol"},{"key":"2364_CR30","doi-asserted-by":"crossref","unstructured":"Li, J.; Zhao, J.; Cao, B.; Fang, J.; Li, X.; Wang, M.; Ba, Y.; Li, X.; Li, Z.; LIU, Z.; Wang, Y.; Cheng, Y.; Bai, C.; Shen, L., A phase I\/II study of first-in-human trial of JAB-21822 (KRAS G12C inhibitor) in advanced solid tumors. J Clin Oncol. 2022, 40 (16_suppl), 3089\u20133089.","DOI":"10.1200\/JCO.2022.40.16_suppl.3089"},{"key":"2364_CR31","doi-asserted-by":"crossref","unstructured":"Gregorc, V.; Gonz\u00e1lez-Cao, M.; Salvagni, S.; Koumarianou, A.; Gil-Bazo, I.; Maio, M.; Viteri, S.; Majem, M.; Guti\u00e9rrez, V.; Caro, R. B.; Sanmamed, M. F.; Zhu, H.; Shen, H.; Wang, Y.; Rosell, R., KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC. J Clin Oncol. 2024, 42 (17_suppl), LBA8511-LBA8511.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8511"},{"issue":"13","key":"2364_CR32","doi-asserted-by":"publisher","first-page":"11024","DOI":"10.1021\/acs.jmedchem.4c00572","volume":"67","author":"X Ma","year":"2024","unstructured":"Ma X, Sloman DL, Duggal R, Anderson KD, Ballard JE, Bharathan I, Brynczka C, Gathiaka S, Henderson TJ, Lyons TW, Miller R, Munsell EV, Orth P, Otte RD, Palani A, Rankic DA, Robinson MR, Sather AC, Solban N, Song XS, Wen X, Xu Z, Yang Y, Yang R, Day PJ, Stoeck A, Bennett DJ, Han Y. Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS(G12C) Inhibitor. J Med Chem. 2024;67(13):11024\u201352.","journal-title":"J Med Chem"},{"issue":"9","key":"2364_CR33","doi-asserted-by":"publisher","first-page":"6940","DOI":"10.1021\/acs.jmedchem.2c00369","volume":"65","author":"JG Kettle","year":"2022","unstructured":"Kettle JG, Bagal SK, Bickerton S, Bodnarchuk MS, Boyd S, Breed J, Carbajo RJ, Cassar DJ, Chakraborty A, Cosulich S, Cumming I, Davies M, Davies NL, Eatherton A, Evans L, Feron L, Fillery S, Gleave ES, Goldberg FW, Hanson L, Harlfinger S, Howard M, Howells R, Jackson A, Kemmitt P, Lamont G, Lamont S, Lewis HJ, Liu L, Niedbala MJ, Phillips C, Polanski R, Raubo P, Robb G, Robinson DM, Ross S, Sanders MG, Tonge M, Whiteley R, Wilkinson S, Yang J, Zhang W. Discovery of AZD4625, a Covalent Allosteric Inhibitor of the Mutant GTPase KRASG12C. J Med Chem. 2022;65(9):6940\u201352.","journal-title":"J Med Chem"},{"issue":"13","key":"2364_CR34","doi-asserted-by":"publisher","first-page":"9147","DOI":"10.1021\/acs.jmedchem.3c00746","volume":"66","author":"JG Kettle","year":"2023","unstructured":"Kettle JG, Bagal SK, Barratt D, Bodnarchuk MS, Boyd S, Braybrooke E, Breed J, Cassar DJ, Cosulich S, Davies M, Davies NL, Deng C, Eatherton A, Evans L, Feron LJ, Fillery S, Gleave ES, Goldberg FW, Cort\u00e9s Gonz\u00e1lez MA, Guerot C, Haider A, Harlfinger S, Howells R, Jackson A, Johnstr\u00f6m P, Kemmitt PD, Koers A, Kondrashov M, Lamont GM, Lamont S, Lewis HJ, Liu L, Mylrea M, Nash S, Niedbala MJ, Peter A, Phillips C, Pike K, Raubo P, Robb GR, Ross S, Sanders MG, Schou M, Simpson I, Steward O. Discovery of AZD4747, a Potent and Selective Inhibitor of Mutant GTPase KRASG12C with Demonstrable CNS Penetration. J Med Chem. 2023;66(13):9147\u201360.","journal-title":"J Med Chem"},{"key":"2364_CR35","doi-asserted-by":"crossref","unstructured":"Zhou, C.; Li, C.; Luo, L.; Li, X.; Jia, K.; He, N.; Mao, S.; Wang, W.; Shao, C.; Liu, X.; Huang, K.; Yu, Y.; Cai, X.; Chen, Y.; Dai, Z.; Li, W.; Yu, J.; Li, J.; Shen, F.; Wang, Z.; He, F.; Sun, X.; Mao, R.; Shi, W.; Zhang, J.; Jiang, T.; Zhang, Z.; Li, F.; Ren, S., Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer. Cancer Cell. 2024, 42 (7), 1286\u20131300 e8.","DOI":"10.1016\/j.ccell.2024.06.001"},{"key":"2364_CR36","doi-asserted-by":"publisher","first-page":"S1273","DOI":"10.1016\/j.annonc.2023.10.025","volume":"34","author":"C Zhou","year":"2023","unstructured":"Zhou C, Li W, Song Z, Zhang Y, Zhang Y, Huang D, Yang Z, Zhou M, Mao R, Huang C, Li X, Wang J. LBA33 A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation. Ann Oncol. 2023;34:S1273.","journal-title":"Ann Oncol"},{"key":"2364_CR37","doi-asserted-by":"crossref","unstructured":"Yan, F.; Jiang, T.; Liang, T.; Cai, L.; Zhang, L.; Xu, X.; Zhao, Y.; Lan, X.; Zhang, X.; Liu, M.; Liu, Q.; Gao, J.; Xie, F.; Gao, X.; Wang, L.; Zhang, J.; Ren, H.; Liu, D.; Le, S.; Tang, L.; Coma, S.; Cheng, Y.; Sanburn, N.; Pachter, J. A.; Zhou, F.; Lan, J.; Lu, Q., Abstract 3318: GFH375 (VS-7375): An oral, selective KRAS G12D (ON\/OFF) inhibitor with potent anti-tumor efficacy. Cancer Res.\u00a02024, 84 (6_Supplement), 3318\u20133318.","DOI":"10.1158\/1538-7445.AM2024-3318"},{"issue":"13","key":"2364_CR38","doi-asserted-by":"publisher","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","volume":"63","author":"JB Fell","year":"2020","unstructured":"Fell JB, Fischer JP, Baer BR, Blake JF, Bouhana K, Briere DM, Brown KD, Burgess LE, Burns AC, Burkard MR, Chiang H, Chicarelli MJ, Cook AW, Gaudino JJ, Hallin J, Hanson L, Hartley DP, Hicken EJ, Hingorani GP, Hinklin RJ, Mejia MJ, Olson P, Otten JN, Rhodes SP, Rodriguez ME, Savechenkov P, Smith DJ, Sudhakar N, Sullivan FX, Tang TP, Vigers GP, Wollenberg L, Christensen JG, Marx MA. Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS(G12C) Inhibitor for the Treatment of Cancer. J Med Chem. 2020;63(13):6679\u201393.","journal-title":"J Med Chem"},{"issue":"8","key":"2364_CR39","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/NEJMoa2303810","volume":"389","author":"Sacher A.; LoRusso P.; Patel M. R.; Miller W. H. , Jr.; Garralda, E.; Forster, M. D.; Santoro, A.; Falcon, A.; Kim, T. W.; Paz-Ares, L.; Bowyer, S.; de Miguel, M.; Han, S. W.; Krebs, M. G.; Lee, J. S.; Cheng, M. L.; Arbour, K.; Massarelli, E.; Choi, Y.; Shi, Z.; Mandlekar, S.; Lin, M. T.; Royer-Joo, S.; Chang, J.; Dharia, N. V.; Schutzman, J. L.; Desai, J.; Investigator, G. O.; Study, G.","year":"2023","unstructured":"Sacher A.; LoRusso P.; Patel M. R.; Miller W. H. , Jr.; Garralda, E.; Forster, M. D.; Santoro, A.; Falcon, A.; Kim, T. W.; Paz-Ares, L.; Bowyer, S.; de Miguel, M.; Han, S. W.; Krebs, M. G.; Lee, J. S.; Cheng, M. L.; Arbour, K.; Massarelli, E.; Choi, Y.; Shi, Z.; Mandlekar, S.; Lin, M. T.; Royer-Joo, S.; Chang, J.; Dharia, N. V.; Schutzman, J. L.; Desai, J.; Investigator, G. O.; Study, G. Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation. N Engl J Med. 2023;389(8):710\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"2364_CR40","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang X, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A, Dahlke JR, Fell JB, Fischer JP, Gunn RJ, Hallin J, Laguer J, Lawson JD, Medwid J, Newhouse B, Nguyen P, O\u2019Leary JM, Olson P, Pajk S, Rahbaek L, Rodriguez M, Smith CR, Tang TP, Thomas NC, Vanderpool D, Vigers GP, Christensen JG, Marx MA. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS(G12D) Inhibitor. J Med Chem. 2022;65(4):3123\u201333.","journal-title":"J Med Chem"},{"issue":"11","key":"2364_CR41","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/s41589-022-01065-9","volume":"18","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Guiley KZ, Shokat KM. Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S). Nat Chem Biol. 2022;18(11):1177\u201383.","journal-title":"Nat Chem Biol"},{"issue":"35","key":"2364_CR42","doi-asserted-by":"publisher","first-page":"15916","DOI":"10.1021\/jacs.2c05377","volume":"144","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Morstein J, Ecker AK, Guiley KZ, Shokat KM. Chemoselective Covalent Modification of K-Ras(G12R) with a Small Molecule Electrophile. J Am Chem Soc. 2022;144(35):15916\u201321.","journal-title":"J Am Chem Soc"},{"issue":"37","key":"2364_CR43","doi-asserted-by":"publisher","first-page":"20403","DOI":"10.1021\/jacs.3c05899","volume":"145","author":"Z Yu","year":"2023","unstructured":"Yu Z, He X, Wang R, Xu X, Zhang Z, Ding K, Zhang ZM, Tan Y, Li Z. Simultaneous Covalent Modification of K-Ras(G12D) and K-Ras(G12C) with Tunable Oxirane Electrophiles. J Am Chem Soc. 2023;145(37):20403\u201311.","journal-title":"J Am Chem Soc"},{"issue":"9","key":"2364_CR44","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41589-024-01565-w","volume":"20","author":"Q Zheng","year":"2024","unstructured":"Zheng Q, Zhang Z, Guiley KZ, Shokat KM. Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D. Nat Chem Biol. 2024;20(9):1114\u201322.","journal-title":"Nat Chem Biol"},{"key":"2364_CR45","unstructured":"AACR New Drugs on the Horizon sessions provide first look at 12 new therapeutics. https:\/\/www.aacrmeetingnews.org\/news\/new-drugs-on-the-horizon-sessions-provide-first-look-at-12-new-therapeutics\/ (accessed 2025\u201305\u201308)."},{"issue":"3","key":"2364_CR46","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1158\/2159-8290.CD-24-0840","volume":"15","author":"AE Maciag","year":"2025","unstructured":"Maciag AE, Stice JP, Wang B, Sharma AK, Chan AH, Lin K, Singh D, Dyba M, Yang Y, Setoodeh S, Smith BP, Ju JH, Jeknic S, Rabara D, Zhang Z, Larsen EK, Esposito D, Denson JP, Ranieri M, Meynardie M, Mehdizadeh S, Alexander PA, Abreu Blanco M, Turner DM, Xu R, Lightstone FC, Wong KK, Stephen AG, Wang K, Simanshu DK, Sinkevicius KW, Nissley DV, Wallace E, McCormick F, Beltran PJ. Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C. Cancer Discov. 2025;15(3):578\u201394.","journal-title":"Cancer Discov"},{"issue":"6_Suppl","key":"2364_CR47","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1158\/1538-7445.AM2024-5948","volume":"84","author":"Y Wang","year":"2024","unstructured":"Wang Y, Neve RM, Staunton J, Webster KR. FMC-376 a dual inhibitor of ON and OFF states of KRASG12C is broadly active in PDX models of resistance. Cancer Res. 2024;84(6_Suppl):5948.","journal-title":"Cancer Res."},{"issue":"5292","key":"2364_CR48","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1126\/science.274.5292.1531","volume":"274","author":"SB Shuker","year":"1996","unstructured":"Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity ligands for proteins: SAR by NMR. Science. 1996;274(5292):1531\u20134.","journal-title":"Science"},{"issue":"14","key":"2364_CR49","doi-asserted-by":"publisher","first-page":"5299","DOI":"10.1073\/pnas.1116510109","volume":"109","author":"T Maurer","year":"2012","unstructured":"Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ, Skelton NJ, Fauber BP, Pan B, Malek S, Stokoe D, Ludlam MJ, Bowman KK, Wu J, Giannetti AM, Starovasnik MA, Mellman I, Jackson PK, Rudolph J, Wang W, Fang G. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A. 2012;109(14):5299\u2013304.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"2364_CR50","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1002\/anie.201201358","volume":"51","author":"Q Sun","year":"2012","unstructured":"Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET, Waterson AG, Lee T, Rossanese OW, Fesik SW. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl. 2012;51(25):6140\u20133.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2364_CR51","doi-asserted-by":"crossref","unstructured":"Br\u00f6ker, J.; Waterson, A. G.; Smethurst, C.; Kessler, D.; B\u00f6ttcher, J.; Mayer, M.; Gmaschitz, G.; Phan, J.; Little, A.; Abbott, J. R.; Sun, Q.; Gmachl, M.; Rudolph, D.; Arnhof, H.; Rumpel, K.; Savarese, F.; Gerstberger, T.; Mischerikow, N.; Treu, M.; Herdeis, L.; Wunberg, T.; Gollner, A.; Weinstabl, H.; Mantoulidis, A.; Kr\u00e4mer, O.; McConnell, D. B.; W. Fesik, S., Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vivo Active KRASG12C Inhibitor. J Med Chem.\u00a02022, 65 (21), 14614\u201314629.","DOI":"10.1021\/acs.jmedchem.2c01120"},{"issue":"1","key":"2364_CR52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s10858-014-9849-8","volume":"60","author":"Q Sun","year":"2014","unstructured":"Sun Q, Phan J, Friberg AR, Camper DV, Olejniczak ET, Fesik SW. A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand. J Biomol NMR. 2014;60(1):11\u20134.","journal-title":"J Biomol NMR"},{"issue":"7968","key":"2364_CR53","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","volume":"619","author":"D Kim","year":"2023","unstructured":"Kim D, Herdeis L, Rudolph D, Zhao Y, B\u00f6ttcher J, Vides A, Ayala-Santos CI, Pourfarjam Y, Cuevas-Navarro A, Xue JY, Mantoulidis A, Br\u00f6ker J, Wunberg T, Schaaf O, Popow J, Wolkerstorfer B, Kropatsch KG, Qu R, de Stanchina E, Sang B, Li C, McConnell DB, Kraut N, Lito P. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth. Nature. 2023;619(7968):160\u20136.","journal-title":"Nature"},{"key":"2364_CR54","doi-asserted-by":"crossref","unstructured":"Tedeschi, A.; Peng, D. H.; Schischlik, F.; Herdeis, L.; Schaaf, O.; Santoro, V.; Gerlach, D.; Savarese, F.; Lipp, J.; Haslinger, C.; Rocchetti, F.; Popow, J.; Huber, H. J.; Wilding, B.; Treu, M.; Fuchs, J.; Broeker, J.; Wunber, T.; Gmachl, M.; Rumpel, K.; Rees, M.; Ron, M.; Roth, J.; Williams, M.; Deckard, C.; Ramamoorthy, V.; Daniele, J. R.; Ajani, J. A.; Meric-Bernstam, F.; Kopetz, S.; Kim, M.; Gibbons, D. L.; Vellano, C. P.; Marszalek, J. R.; Heffernan, T. P.; McConnell, D.; Pearson, M.; Kraut, N.; Rudolph, D., Abstract 3317: KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harbouring KRASG12V mutations and KRAS wild-type amplifications. Cancer Res.\u00a02024, 84 (6_Supplement), 3317\u20133317.","DOI":"10.1158\/1538-7445.AM2024-3317"},{"key":"2364_CR55","doi-asserted-by":"crossref","unstructured":"Tedeschi, A.; Herdeis, L.; Santoro, V.; Savarese, F.; Wilding, B.; Treu, M.; Fuchs, J.; Br\u00f6ker, J.; Wunberg, T.; Gmachl, M.; Klaus, R.; Schischlik, F.; Lipp, J.; Peng, D. H.; Williams, M.; Deckard, C.; Ramamoorthy, V.; Daniele, J. R.; Ajani, J. A.; Meric-Bernstam, F.; Vellano, C. P.; Marszalek, J. R.; Heffernan, T. P.; McConnell, D.; Pearson, M.; Kraut, N.; Rudolph, D., Abstract A085: BI KRASmulti, a first-in-class, orally bioavailable and direct inhibitor of diverse oncogenic KRAS variants drives tumor regression in preclinical models and validates wild-type amplified KRAS as a therapeutic target. Molecular Cancer Therapeutics. 2023, 22 (12_Supplement), A085-A085.","DOI":"10.1158\/1535-7163.TARG-23-A085"},{"key":"2364_CR56","doi-asserted-by":"publisher","first-page":"S468","DOI":"10.1016\/j.annonc.2023.09.1851","volume":"34","author":"J Heymach","year":"2023","unstructured":"Heymach J, Kotecki N, Prenen H, Alonso G, Lindsay CR, Barve M, Thamer C, Eigenbrod-Giese S, Marotti MA, Van Lancker G. 665P First-in-human, phase Ia\/b, dose-escalation\/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation. Ann Oncol. 2023;34:S468.","journal-title":"Ann Oncol"},{"issue":"6659","key":"2364_CR57","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1126\/science.adg9652","volume":"381","author":"CJ Schulze","year":"2023","unstructured":"Schulze CJ, Seamon KJ, Zhao Y, Yang YC, Cregg J, Kim D, Tomlinson A, Choy TJ, Wang Z, Sang B, Pourfarjam Y, Lucas J, Cuevas-Navarro A, Ayala-Santos C, Vides A, Li C, Marquez A, Zhong M, Vemulapalli V, Weller C, Gould A, Whalen DM, Salvador A, Milin A, Saldajeno-Concar M, Dinglasan N, Chen A, Evans J, Knox JE, Koltun ES, Singh M, Nichols R, Wildes D, Gill AL, Smith JAM, Lito P. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS. Science. 2023;381(6659):794\u20139.","journal-title":"Science"},{"issue":"8013","key":"2364_CR58","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41586-024-07379-z","volume":"629","author":"UN Wasko","year":"2024","unstructured":"Wasko UN, Jiang J, Dalton TC, Curiel-Garcia A, Edwards AC, Wang Y, Lee B, Orlen M, Tian S, Stalnecker CA, Drizyte-Miller K, Menard M, Dilly J, Sastra SA, Palermo CF, Hasselluhn MC, Decker-Farrell AR, Chang S, Jiang L, Wei X, Yang YC, Helland C, Courtney H, Gindin Y, Muonio K, Zhao R, Kemp SB, Clendenin C, Sor R, Vostrejs WP, Hibshman PS, Amparo AM, Hennessey C, Rees MG, Ronan MM, Roth JA, Brodbeck J, Tomassoni L, Bakir B, Socci ND, Herring LE, Barker NK, Wang J, Cleary JM, Wolpin BM, Chabot JA, Kluger MD, Manji GA, Tsai KY, Sekulic M, Lagana SM, Califano A, Quintana E, Wang Z, Smith JAM, Holderfield M, Wildes D, Lowe SW, Badgley MA, Aguirre AJ, Vonderheide RH, Stanger BZ, Baslan T, Der CJ, Singh M, Olive KP. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Nature. 2024;629(8013):927\u201336.","journal-title":"Nature"},{"issue":"1","key":"2364_CR59","doi-asserted-by":"publisher","first-page":"7554","DOI":"10.1038\/s41467-024-51828-2","volume":"15","author":"MJ Nokin","year":"2024","unstructured":"Nokin MJ, Mira A, Patrucco E, Ricciuti B, Cousin S, Soubeyran I, San Jose S, Peirone S, Caizzi L, Vietti Michelina S, Bourdon A, Wang X, Alvarez-Villanueva D, Martinez-Iniesta M, Vidal A, Rodrigues T, Garcia-Macias C, Awad MM, Nadal E, Villanueva A, Italiano A, Cereda M, Santamaria D, Ambrogio C. RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade. Nat Commun. 2024;15(1):7554.","journal-title":"Nat Commun"},{"issue":"8013","key":"2364_CR60","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s41586-024-07205-6","volume":"629","author":"M Holderfield","year":"2024","unstructured":"Holderfield M, Lee BJ, Jiang J, Tomlinson A, Seamon KJ, Mira A, Patrucco E, Goodhart G, Dilly J, Gindin Y, Dinglasan N, Wang Y, Lai LP, Cai S, Jiang L, Nasholm N, Shifrin N, Blaj C, Shah H, Evans JW, Montazer N, Lai O, Shi J, Ahler E, Quintana E, Chang S, Salvador A, Marquez A, Cregg J, Liu Y, Milin A, Chen A, Ziv TB, Parsons D, Knox JE, Klomp JE, Roth J, Rees M, Ronan M, Cuevas-Navarro A, Hu F, Lito P, Santamaria D, Aguirre AJ, Waters AM, Der CJ, Ambrogio C, Wang Z, Gill AL, Koltun ES, Smith JAM, Wildes D, Singh M. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature. 2024;629(8013):919\u201326.","journal-title":"Nature"},{"issue":"11","key":"2364_CR61","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1158\/2159-8290.CD-24-0421","volume":"14","author":"HA Araujo","year":"2024","unstructured":"Araujo HA, Pechuan-Jorge X, Zhou T, Do MT, Hu X, Rojas Alvarez FR, Salvatierra ME, Ibarguen HP, Lee R, Raghulan R, Shah H, Moreno Ayala MA, Chen K, Tovbis Shifrin N, Wu S, Solis Soto LM, Negrao MV, Gibbons DL, Hong DS, Roth JA, Heymach JV, Zhang J, Jiang J, Singh M, Smith JAM, Quintana E, Skoulidis F. Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung Cancer. Cancer Discov. 2024;14(11):2183\u2013208.","journal-title":"Cancer Discov"},{"issue":"18","key":"2364_CR62","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1158\/0008-5472.CAN-24-1926","volume":"84","author":"AJ Aguirre","year":"2024","unstructured":"Aguirre AJ, Stanger BZ, Maitra A. Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer. Cancer Res. 2024;84(18):2950\u20133.","journal-title":"Cancer Res"},{"key":"2364_CR63","doi-asserted-by":"crossref","unstructured":"Nichols, R. J.; Yang, Y. C.; Cregg, J.; Schulze, C. J.; Wang, Z.; Dua, R.; Jiang, J.; Garrenton, L. S.; Nasholm, N.; Bermingham, A.; Knox, J. E.; Seamon, K.; Longhi, M.; Chou, K.-J.; Li, S.; Wildes, D. P.; Singh, M.; Koltun, E. S.; Gill, A. L.; Smith, J. A. M., Abstract 3595: RMC-6291, a next-generation tri-complex KRASG12C(ON) inhibitor, outperforms KRASG12C(OFF) inhibitors in preclinical models of KRASG12C cancers. Cancer Res.\u00a02022, 82 (12_Supplement), 3595\u20133595.","DOI":"10.1158\/1538-7445.AM2022-3595"},{"key":"2364_CR64","doi-asserted-by":"crossref","unstructured":"Jiang, L.; Menard, M.; Weller, C.; Wang, Z.; Burnett, L.; Aronchik, I.; Steele, S.; Flagella, M.; Zhao, R.; Evans, J. W. W.; Chin, S.; Chou, K.-J.; Mu, Y.; Longhi, M.; McDowell, L.; Knox, J. E.; Gill, A.; Smith, J. A.; Singh, M.; Quintana, E.; Jiang, J., Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers. Cancer Res.\u00a02023, 83 (7_Supplement), 526\u2013526.","DOI":"10.1158\/1538-7445.AM2023-526"},{"key":"2364_CR65","doi-asserted-by":"crossref","unstructured":"Zhe Chen, A. E., Bianca Lee, Jay Dinglasan, Nilufar Montazer, Jim Cregg, Anne Edwards, Kate Sanders, Jacqueline A. Smith, David Wildes, Mallika Singh, Zhican Wang, Jingjing Jiang, RMC-5127, a first-in-class, orally bioavailable mutant-selective RASG12V(ON) inhibitor is central nervous system (CNS)-penetrant and demonstrates anti-tumor activity in a preclinical intracranial xenograft model. Cancer Res. 2024, 84(6_Suppl) (Abstract nr 3340).","DOI":"10.1158\/1538-7445.AM2024-3340"},{"key":"2364_CR66","unstructured":"Medicines, R. https:\/\/ir.revmed.com\/news-releases\/news-release-details\/revolution-medicines-present-preclinical-data-upcoming-american (accessed 2023\u201304\u201306)."},{"key":"2364_CR67","doi-asserted-by":"crossref","unstructured":"Zeng, M.; Xiong, Y.; Safaee, N.; Nowak, R. P.; Donovan, K. A.; Yuan, C. J.; Nabet, B.; Gero, T. W.; Feru, F.; Li, L. B.; Gondi, S.; Ombelets, L. J.; Quan, C. S.; J\u00e4nne, P. A.; Kostic, M.; Scott, D. A.; Westover, K. D.; Fischer, E. S.; Gray, N. S., Exploring Targeted Degradation Strategy for Oncogenic KRAS<SUP>G12C<\/SUP>. Cell Chem Biol. 2020, 27 (1), 19-+.","DOI":"10.1016\/j.chembiol.2019.12.006"},{"issue":"8","key":"2364_CR68","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1021\/acscentsci.0c00411","volume":"6","author":"MJ Bond","year":"2020","unstructured":"Bond MJ, Chu L, Nalawansha DA, Li K, Crews CM. Targeted Degradation of Oncogenic KRAS<SUP>G12C<\/SUP> by VHL-Recruiting PROTACs. Acs Central Sci. 2020;6(8):1367\u201375.","journal-title":"Acs Central Sci"},{"key":"2364_CR69","doi-asserted-by":"crossref","unstructured":"Yang F, Wen Y, Wang C, Zhou Y, Zhou Y, Zhang Z-M, Liu T, Lu X. Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC. Eur J Med Chem. 2022;230:114088.","DOI":"10.1016\/j.ejmech.2021.114088"},{"key":"2364_CR70","doi-asserted-by":"publisher","first-page":"115857","DOI":"10.1016\/j.ejmech.2023.115857","volume":"261","author":"N Yang","year":"2023","unstructured":"Yang N, Fan ZY, Sun SY, Hu XT, Mao YQ, Jia CK, Cai X, Xu TT, Li BK, Li Y, Han LB, Wei T, Qian XH, Qin WJ, Li PY, Zheng ZB, Li S. Discovery of highly potent and selective KRAS degraders by VHL-recruiting PROTACs for the treatment of tumors with KRAS-Mutation. Eur J Med Chem. 2023;261:115857.","journal-title":"Eur J Med Chem."},{"key":"2364_CR71","doi-asserted-by":"crossref","unstructured":"Nagashima, T.; Yoshinari, T.; Nishizono, Y.; Tasaki, M.; Inamura, K.; Ishioka, H.; Suzuki, A.; Osaki, F.; Yamanaka, Y.; Hayakawa, M., Abstract 5735: Novel KRAS G12D degrader ASP3082 demonstrates in vivo, dose-dependent KRAS degradation, KRAS pathway inhibition, and antitumor efficacy in multiple KRAS G12D-mutated cancer models. Cancer Res. 2023, 83 (7_Supplement), 5735\u20135735.","DOI":"10.1158\/1538-7445.AM2023-5735"},{"issue":"6715","key":"2364_CR72","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1126\/science.adm8684","volume":"385","author":"J Popow","year":"2024","unstructured":"Popow J, Farnaby W, Gollner A, Kofink C, Fischer G, Wurm M, Zollman D, Wijaya A, Mischerikow N, Hasenoehrl C, Prokofeva P, Arnhof H, Arce-Solano S, Bell S, Boeck G, Diers E, Frost AB, Goodwin-Tindall J, Karolyi-Oezguer J, Khan S, Klawatsch T, Koegl M, Kousek R, Kratochvil B, Kropatsch K, Lauber AA, Mclennan R, Olt S, Peter D, Petermann O, Roessler V, Stolt-Bergner P, Strack P, Strauss E, Trainor N, Vetma V, Whitworth C, Zhong SY, Quant J, Weinstabl H, Kuster B, Ettmayer P, Ciulli A. Targeting cancer with small-molecule pan-KRAS degraders. Science. 2024;385(6715):1338\u201347.","journal-title":"Science"},{"key":"2364_CR73","doi-asserted-by":"crossref","unstructured":"Zhang, Z.; Rohweder, P. J.; Ongpipattanakul, C.; Basu, K.; Bohn, M. F.; Dugan, E. J.; Steri, V.; Hann, B.; Shokat, K. M.; Craik, C. S., A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. Cancer Cell. 2022, 40 (9), 1060\u20131069 e7.","DOI":"10.1016\/j.ccell.2022.07.005"},{"key":"2364_CR74","doi-asserted-by":"crossref","unstructured":"Li DZ, Geng K, Hao Y, Gu JJ, Kumar S, Olson AT, Kuismi CC, Kim HM, Pan YW, Sherman F, et al. Targeted degradation of oncogenic KRASG12V triggers antitumor immunity in lung cancer models. J Clin Invest. 2025;135(2):e174249.","DOI":"10.1172\/JCI174249"},{"issue":"5","key":"2364_CR75","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.cancergen.2016.03.001","volume":"209","author":"A Biernacka","year":"2016","unstructured":"Biernacka A, Tsongalis PD, Peterson JD, de Abreu FB, Black CC, Gutmann EJ, Liu X, Tafe LJ, Amos CI, Tsongalis GJ. The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinoma. Cancer Genet. 2016;209(5):195\u20138.","journal-title":"Cancer Genet"},{"key":"2364_CR76","doi-asserted-by":"crossref","unstructured":"Skoulidis, F.; Li, B. T.; Dy, G. K.; Price, T. J.; Falchook, G. S.; Wolf, J.; Italiano, A.; Schuler, M.; Borghaei, H.; Barlesi, F.; Kato, T.; Curioni-Fontecedro, A.; Sacher, A.; Spira, A.; Ramalingam, S. S.; Takahashi, T.; Besse, B.; Anderson, A.; Ang, A.; Tran, Q.; Mather, O.; Henary, H.; Ngarmchamnanrith, G.; Friberg, G.; Velcheti, V.; Govindan, R., Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N Engl J Med. 2021, 384 (25), 2371\u20132381.","DOI":"10.1056\/NEJMoa2103695"},{"issue":"2","key":"2364_CR77","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA Janne","year":"2022","unstructured":"Janne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SI, Pacheco JM, Johnson ML, Sabari JK, Leventakos K, Yau E, Bazhenova L, Negrao MV, Pennell NA, Zhang J, Anderes K, Der-Torossian H, Kheoh T, Velastegui K, Yan X, Christensen JG, Chao RC, Spira AI. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS(G12C) Mutation. N Engl J Med. 2022;387(2):120\u201331.","journal-title":"N Engl J Med"},{"issue":"10378","key":"2364_CR78","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","volume":"401","author":"AJ de Langen","year":"2023","unstructured":"de Langen AJ, Johnson ML, Mazieres J, Dingemans AC, Mountzios G, Pless M, Wolf J, Schuler M, Lena H, Skoulidis F, Yoneshima Y, Kim SW, Linardou H, Novello S, van der Wekken AJ, Chen Y, Peters S, Felip E, Solomon BJ, Ramalingam SS, Dooms C, Lindsay CR, Ferreira CG, Blais N, Obiozor CC, Wang Y, Mehta B, Varrieur T, Ngarmchamnanrith G, Stollenwerk B, Waterhouse D, Paz-Ares L, CodeBrea KI. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023;401(10378):733\u201346.","journal-title":"Lancet"},{"key":"2364_CR79","unstructured":"Cancer Genome Atlas Research Network. Electronic address, a. a. d. h. e.; Cancer Genome Atlas Research, N., Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2017, 32 (2), 185\u2013203 e13."},{"key":"2364_CR80","doi-asserted-by":"crossref","unstructured":"Strickler, J. H.; Satake, H.; George, T. J.; Yaeger, R.; Hollebecque, A.; Garrido-Laguna, I.; Schuler, M.; Burns, T. F.; Coveler, A. L.; Falchook, G. S.; Vincent, M.; Sunakawa, Y.; Dahan, L.; Bajor, D.; Rha, S. Y.; Lemech, C.; Juric, D.; Rehn, M.; Ngarmchamnanrith, G.; Jafarinasabian, P.; Tran, Q.; Hong, D. S., Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2023, 388 (1), 33\u201343.","DOI":"10.1056\/NEJMoa2208470"},{"issue":"25","key":"2364_CR81","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/JCO.23.00434","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab TS, Yaeger R, Spira AI, Pelster MS, Sabari JK, Hafez N, Barve M, Velastegui K, Yan X, Shetty A, Der-Torossian H, Pant S. Adagrasib in Advanced Solid Tumors Harboring a KRAS(G12C) Mutation. J Clin Oncol. 2023;41(25):4097\u2013106.","journal-title":"J Clin Oncol"},{"key":"2364_CR82","doi-asserted-by":"crossref","unstructured":"Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, ant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS (G12C)-Mutant Colorectal Cancer. JCO Precis Oncol. 2021;5:20.00256.","DOI":"10.1200\/PO.20.00256"},{"issue":"1","key":"2364_CR83","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(21)00605-7","volume":"23","author":"MG Fakih","year":"2022","unstructured":"Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH, Hong DS, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Sotorasib for previously treated colorectal cancers with KRAS(G12C) mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2022;23(1):115\u201324.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2364_CR84","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, Klempner SJ. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;388(1):44\u201354.","journal-title":"N Engl J Med"},{"issue":"12","key":"2364_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110993","volume":"39","author":"MB Ryan","year":"2022","unstructured":"Ryan MB, Coker O, Sorokin A, Fella K, Barnes H, Wong E, Kanikarla P, Gao F, Zhang Y, Zhou L, Kopetz S, Corcoran RB. KRAS(G12C)-independent feedback activation of wild-type RAS constrains KRAS(G12C) inhibitor efficacy. Cell Rep. 2022;39(12): 110993.","journal-title":"Cell Rep"},{"key":"2364_CR86","doi-asserted-by":"crossref","unstructured":"Ryan, M. B.; Fece de la Cruz, F.; Phat, S.; Myers, D. T.; Wong, E.; Shahzade, H. A.; Hong, C. B.; Corcoran, R. B., Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRAS(G12C) Inhibition. Clin Cancer Res. 2020, 26 (7), 1633\u20131643.","DOI":"10.1158\/1078-0432.CCR-19-3523"},{"issue":"8","key":"2364_CR87","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","volume":"10","author":"V Amodio","year":"2020","unstructured":"Amodio V, Yaeger R, Arcella P, Cancelliere C, Lamba S, Lorenzato A, Arena S, Montone M, Mussolin B, Bian Y, Whaley A, Pinnelli M, Murciano-Goroff YR, Vakiani E, Valeri N, Liao WL, Bhalkikar A, Thyparambil S, Zhao HY, de Stanchina E, Marsoni S, Siena S, Bertotti A, Trusolino L, Li BT, Rosen N, Di Nicolantonio F, Bardelli A, Misale S. EGFR Blockade Reverts Resistance to KRAS(G12C) Inhibition in Colorectal Cancer. Cancer Discov. 2020;10(8):1129\u201339.","journal-title":"Cancer Discov"},{"issue":"23","key":"2364_CR88","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Chan E, Chao J, Saportas Y, Tran Q, Cremolini C, Pietrantonio F. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023;389(23):2125\u201339.","journal-title":"N Engl J Med"},{"issue":"1","key":"2364_CR89","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","volume":"30","author":"Desai J.; Alonso G.; Kim S. H.; Cervantes A.; Karasic T.; Medina L.; Shacham-Shmueli E.; Cosman R.; Falcon A.; Gort E.; Guren T.; Massarelli E.; Miller W. H. , Jr.; Paz-Ares, L.; Prenen, H.; Amatu, A.; Cremolini, C.; Kim, T. W.; Moreno, V.; Ou, S. I.; Passardi, A.; Sacher, A.; Santoro, A.; Stec, R.; Ulahannan, S.; Arbour, K.; Lorusso, P.; Luo, J.; Patel, M. R.; Choi, Y.; Shi, Z.; Mandlekar, S.; Lin, M. T.; Royer-Joo, S.; Chang, J.; Jun, T.; Dharia, N. V.; Schutzman, J. L.; Investigator, G. O.; Study, G.; Han, S. W.","year":"2024","unstructured":"Desai J.; Alonso G.; Kim S. H.; Cervantes A.; Karasic T.; Medina L.; Shacham-Shmueli E.; Cosman R.; Falcon A.; Gort E.; Guren T.; Massarelli E.; Miller W. H. , Jr.; Paz-Ares, L.; Prenen, H.; Amatu, A.; Cremolini, C.; Kim, T. W.; Moreno, V.; Ou, S. I.; Passardi, A.; Sacher, A.; Santoro, A.; Stec, R.; Ulahannan, S.; Arbour, K.; Lorusso, P.; Luo, J.; Patel, M. R.; Choi, Y.; Shi, Z.; Mandlekar, S.; Lin, M. T.; Royer-Joo, S.; Chang, J.; Jun, T.; Dharia, N. V.; Schutzman, J. L.; Investigator, G. O.; Study, G.; Han, S. W. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2024;30(1):271\u20138.","journal-title":"Nat Med"},{"key":"2364_CR90","doi-asserted-by":"publisher","first-page":"S493","DOI":"10.1016\/j.annonc.2024.08.682","volume":"35","author":"BC Cho","year":"2024","unstructured":"Cho BC, Lu S, Lee MA, Song Z, Park JJW, Lim SM, Li Z, Zhao J, Richardson G, Zhang Y, Zhang J, Liu A, Chen C, Wang J, Chen J, Wang A, Zhang J, Chen ZG, Mok TSK, Johnson ML. 615MO Phase I\/II study of D3S\u2013001, a second generation KRAS G12C inhibitor in advanced\/metastatic solid tumors with KRAS G12C mutations. Ann Oncol. 2024;35:S493.","journal-title":"Ann Oncol"},{"key":"2364_CR91","doi-asserted-by":"publisher","unstructured":"Cho BC, Lu S, Lee MA, Song Z, Park JJ, Lim SM, Li Z, Zhao J, Richardson G, Zhang Y, Zhang J, Liu A, Loong HH, Chen C, Wang J, Shen Y, Fan Z, Chen Q, Wang H, Zhang J, Chen ZJ, Johnson ML, Mok T. D3S-001 in advanced solid tumors with KRAS(G12C) mutations: a phase 1 trial. Nat Med. 2025.\u00a0https:\/\/doi.org\/10.1038\/s41591-025-03688-6.","DOI":"10.1038\/s41591-025-03688-6"},{"key":"2364_CR92","doi-asserted-by":"crossref","unstructured":"Zhou, Q.; Meng, X.; Sun, L.; Huang, D.; Yang, N.; Yu, Y.; Zhao, M.; Zhuang, W.; Hu, Y.; Pan, Y.; Sun, M.; Shan, J.; Guo, R.; Chu, Q.; Xu, C.; Lin, J.; Huang, J.; Huang, M.; Zhang, S.; Wu, Y. L., OA14.05 KRAS G12C Inhibitor IBI351 In Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Pivotal Phase 2 Study. J Thoracic Oncol. 2024, 19 (10), S42.","DOI":"10.1016\/j.jtho.2024.09.074"},{"key":"2364_CR93","doi-asserted-by":"crossref","unstructured":"Shi, Y.; Fang, J.; Xing, L. G.; Yao, Y.; Zhang, J.; Liu, L.; Wang, Y. S.; Hu, C. L.; Xiong, J. P.; Liu, Z. H.; Yang, R. X.; Wang, Z.; Zhao, E. F.; Wang, M. Z.; Zhao, Y. Q.; Tang, K. J.; Li, Z. H.; Song, Z. B., A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation. J Clin Oncol.\u00a02024, 42 (36_Suppl), 468214\u2013468214.","DOI":"10.1200\/JCO.2024.42.36_suppl.468214"},{"key":"2364_CR94","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1038\/s41591-024-03401-z","volume":"31","author":"Y Shi","year":"2025","unstructured":"Shi Y, Fang J, Xing L, Yao Y, Zhang J, Liu L, Wang Y, Hu C, Xiong J, Liu Z, Yang R, Wang Z, Zhao E, Wang M, Zhao Y, Tang K, Li Z, Song Z, Li Y, Zhuang W, Jin B, Cheng Y, Hu Y, Gu Y, Wu L, Ma R, Yu Q, Yu Y, Zhao J, Zhao H, Lv D, Shang Y, Xing P, Zhou J, Li X, Liu Z, Dai Z, Xia G, Chen X, Ba Y, Bai C, Li Q, An G, Hu W, Wang Y, Wang-Gillam A, Ding Y, Li Q, Rao Z. Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial. Nat Med. 2025;31:894\u2013900.","journal-title":"Nat Med."},{"key":"2364_CR95","doi-asserted-by":"crossref","unstructured":"Jian Li, L. S., Yanhong Gu, Antonio Calles, Lin Wu, Yi Ba, Zhi-hua Li, Chunmei Bai, Yu Yao, Ayala Hubert, Julia Martinez Perez, Jon Zugazagoitia, Yuli Ding, Sumei Liu, Zhiyue Rao, Zhiwen He, Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors. J Clin Oncol.\u00a02024, 42 (Issue 3_suppl), 604.","DOI":"10.1200\/JCO.2024.42.3_suppl.604"},{"key":"2364_CR96","doi-asserted-by":"crossref","unstructured":"Rebecca Suk Heist, T. K., Yonina R. Murciano-Goroff, Antoine Hollebecque, Philippe Alexandre Cassier, Ji-Youn Han, Diego Tosi, Adrian G. Sacher, Timothy F. Burns, Alexander I. Spira, Carlos A. Gomez-Roca, Toshio Shimizu, Natraj Reddy Ammakkanavar, Joshua K. Sabari, Misako Nagasaka, Aaron Alan Fink, Aaron Chen, Melinda D Willard, Geoffrey R. Oxnard, Yasutoshi Kuboki, Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors. J Clin Oncol.\u00a02024, 42 (Number 16_suppl).","DOI":"10.1200\/JCO.2024.42.16_suppl.3007"},{"key":"2364_CR97","doi-asserted-by":"crossref","unstructured":"Zhang, Y.; Zhou, L.; Gong, Y.; Huang, M.; Tang, M.; Liu, Y.; Yu, M.; Xiu, W.; Liang, X.; Liu, X.; Fu, X.-Y.; Lu, Y., Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors. J Clin Oncol.\u00a02023, 41 (16_suppl), 9112\u20139112.","DOI":"10.1200\/JCO.2023.41.16_suppl.9112"},{"key":"2364_CR98","doi-asserted-by":"crossref","unstructured":"Dong, X.; Meng, X.; Zhang, Y.; Wang, Y.; Chen, J.; Han, L.; Wang, Q.; Lin, Z.; Wei, H.; Lin, S.; Li, C.; Wu, Q., Abstract CT119: Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC). Cancer Res.\u00a02024, 84 (7_Supplement), CT119-CT119.","DOI":"10.1158\/1538-7445.AM2024-CT119"},{"issue":"8_Suppl_2","key":"2364_CR99","doi-asserted-by":"publisher","first-page":"CT138","DOI":"10.1158\/1538-7445.AM2025-CT138","volume":"85","author":"X Meng","year":"2025","unstructured":"Meng X, Zhang Y, Wang Y, Han L, Chen J, Wang Q, Lin Z, Feng S, Su Z, Zhang X, Dong X. Safety and efficacy of HS-10370 in KRAS G12C-mutated advanced solid tumors: Updated results from phase 1 study. Cancer Res. 2025;85(8_Suppl_2):CT138.","journal-title":"Cancer Res."},{"issue":"8","key":"2364_CR100","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S2213-2600(24)00110-3","volume":"12","author":"Li Z.; Dang X.; Huang D.; Jin S.; Li W.; Shi J.; Wang X.; Zhang Y.; Song Z.; Zhang J.; Zhuang W.; Liu X.; Jiang L.; Meng X.; Zhao M.; Zhou J.; Zhang L.; Wang P.; Luo H.; Yang J.; Cang S.; Wang X.; Zhang L.; Lu S.; Group D. S.","year":"2024","unstructured":"Li Z.; Dang X.; Huang D.; Jin S.; Li W.; Shi J.; Wang X.; Zhang Y.; Song Z.; Zhang J.; Zhuang W.; Liu X.; Jiang L.; Meng X.; Zhao M.; Zhou J.; Zhang L.; Wang P.; Luo H.; Yang J.; Cang S.; Wang X.; Zhang L.; Lu S.; Group D. S. Garsorasib in patients with KRAS(G12C)-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial. Lancet Respir Med. 2024;12(8):589\u201398.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2364_CR101","doi-asserted-by":"publisher","first-page":"102273","DOI":"10.1016\/j.esmoop.2024.102273","volume":"9","author":"CI Rojas","year":"2024","unstructured":"Rojas CI, Lugowska I, Juergens R, Sacher A, Weindler S, Sendur MAN, Dziadziuszko R, Pal A, Alvarez EC, Ahern ES, Lakhani N, Chen L, Jemielita T, Choi SY, Stathis A. 44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC. ESMO Open. 2024;9(1):102273.","journal-title":"ESMO Open."},{"key":"2364_CR102","doi-asserted-by":"crossref","unstructured":"J\u00e4nne, P. A.; Bigot, F.; Papadopoulos, K.; Eberst, L.; Sommerhalder, D.; Lebellec, L.; Voon, P. J.; Pellini, B.; Kalinka, E.; Arbour, K.; Herzberg, B.; Boni, V.; Bordenave, S.; Lee, H. W.; Ou, S. I.; Riess, J. W.; Beck, J. T.; Ponz-Sarvise, M.; Ascierto, P. A.; Choi, Y. J.; Yang, M.; Bao, L.; Raman, R.; Yang, L.; Mu, Y.; Wong, S.; Dua, R.; Johnson, M., Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment. Molecular Cancer Therapeut. 2023, 22 (12_Supplement), PR014-PR014.","DOI":"10.1158\/1535-7163.TARG-23-PR014"},{"issue":"7790","key":"2364_CR103","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","volume":"577","author":"JY Xue","year":"2020","unstructured":"Xue JY, Zhao Y, Aronowitz J, Mai TT, Vides A, Qeriqi B, Kim D, Li C, de Stanchina E, Mazutis L, Risso D, Lito P. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition. Nature. 2020;577(7790):421\u20135.","journal-title":"Nature"},{"key":"2364_CR104","doi-asserted-by":"publisher","first-page":"S486","DOI":"10.1016\/j.annonc.2024.08.675","volume":"35","author":"W Park","year":"2024","unstructured":"Park W, Kasi A, Spira AI, Berlin JD, Wang JS, Herzberg B, Kuboki Y, Kitano S, Pelster M, Goldman JW, Morgensztern D, Kondo S, J\u00e4nne PA, Fujii H, Lee HJ, Gill S, Saci A, Lorusso P, Tolcher AW. 608O Preliminary safety and clinical activity of ASP3082, a first-in-class, KRAS G12D selective protein degrader in adults with advanced pancreatic (PC), colorectal (CRC), and non-small cell lung cancer (NSCLC). Ann Oncol. 2024;35:S486\u20137.","journal-title":"Ann Oncol"},{"issue":"3","key":"2364_CR105","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M Bekes","year":"2022","unstructured":"Bekes M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181\u2013200.","journal-title":"Nat Rev Drug Discov"},{"key":"2364_CR106","doi-asserted-by":"crossref","unstructured":"Knox, J. E.; Burnett, G. L.; Weller, C.; Jiang, L.; Zhang, D.; Vita, N.; Marquez, A.; Seamon, K. J.; Gould, A.; Menard, M.; Quintana, E.; Chen, Z.; Wang, Z.; Wang, Z.; Koltun, E. S.; Singh, M.; Jiang, J.; Wildes, D.; Smith, J. A. M.; Gill, A. L., Abstract ND03: Discovery of RMC-9805, an oral, covalent tri-complex KRASG12D(ON) inhibitor. Cancer Res.\u00a02024, 84 (7_Supplement), ND03-ND03.","DOI":"10.1158\/1538-7445.AM2024-ND03"},{"issue":"2","key":"2364_CR107","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","volume":"11","author":"T Isermann","year":"2025","unstructured":"Isermann T, Sers C, Der CJ, Papke B. KRAS inhibitors: resistance drivers and combinatorial strategies. Trends in Cancer. 2025;11(2):91\u2013116.","journal-title":"Trends in Cancer"},{"key":"2364_CR108","unstructured":"Medicines, R. First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC. https:\/\/ir.revmed.com\/news-releases\/news-release-details\/revolution-medicines-presents-initial-data-rmc-9805-monotherapy (accessed 2024\u201310\u201325)."},{"key":"2364_CR109","unstructured":"Medicines, R. Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting. https:\/\/ir.revmed.com\/news-releases\/news-release-details\/revolution-medicines-presents-initial-data-zoldonrasib-rmc-9805 (accessed 2025\u201304\u201327)."},{"key":"2364_CR110","doi-asserted-by":"crossref","unstructured":"Spira, A. I.; Starodub, A. N.; Arbour, K. C.; Sommerhalder, D.; Wolpin, B. M.; Barve, M.; Garrido-Laguna, I.; Punekar, S.; Pelster, M.; Kar, S.; Wong, J.; Lin, T.; Raman, R.; Tao, L.; Salman, Z.; Wang, X.; Gustafson, W. C.; Hong, D. S., Abstract PR010: Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236\u2013001. Molecular Cancer Therapeut.\u00a02023, 22 (12_Supplement), PR010-PR010.","DOI":"10.1158\/1535-7163.TARG-23-PR010"},{"key":"2364_CR111","unstructured":"Medicines, R. Compelling Phase 1\/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial. https:\/\/ir.revmed.com\/news-releases\/news-release-details\/revolution-medicines-provides-clinical-updates-its-rason (accessed 2024\u201309\u201302)."},{"key":"2364_CR112","unstructured":"Medicines, R. Phase 1\/1b proof-of-concept for RMC-6236 monotherapy in previously treated non-small cell lung cancer supports Phase 3 RASolve 301 clinical trial expected to be initiated in Q1 2025. https:\/\/ir.revmed.com\/news-releases\/news-release-details\/revolution-medicines-provides-clinical-updates-its-rason (accessed 2024\u201309\u201302)."},{"issue":"11","key":"2364_CR113","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","volume":"14","author":"J Dilly","year":"2024","unstructured":"Dilly J, Hoffman MT, Abbassi L, Li Z, Paradiso F, Parent BD, Hennessey CJ, Jordan AC, Morgado M, Dasgupta S, Uribe GA, Yang A, Kapner KS, Hambitzer FP, Qiang L, Feng H, Geisberg J, Wang J, Evans KE, Lyu H, Schalck A, Feng N, Lopez AM, Bristow CA, Kim MP, Rajapakshe KI, Bahrambeigi V, Roth JA, Garg K, Guerrero PA, Stanger BZ, Cristea S, Lowe SW, Baslan T, Van Allen EM, Mancias JD, Chan E, Anderson A, Katlinskaya YV, Shalek AK, Hong DS, Pant S, Hallin J, Anderes K, Olson P, Heffernan TP, Chugh S, Christensen JG, Maitra A, Wolpin BM, Raghavan S, Nowak JA, Winter PS, Dougan SK, Aguirre AJ. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer. Cancer Discov. 2024;14(11):2135\u201361.","journal-title":"Cancer Discov"},{"key":"2364_CR114","doi-asserted-by":"crossref","unstructured":"Li, B. T.; Clarke, J. M.; Felip, E.; Ruffinelli, J. C.; Garrido, P.; Zugazagoitia, J.; Goldberg, S. B.; Ramalingam, S. S.; Victoria, I.; Puri, S.; Gandara, D. R.; Kormany, W.; Edmonds, S.; Palmer, K.; Gupta, R. G.; Govindan, R., Sotorasib plus carboplatin and pemetrexed in <i>KRAS<\/i> G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial. J Clin Oncol.\u00a02024, 42 (16_suppl), 8512\u20138512.","DOI":"10.1200\/JCO.2024.42.16_suppl.8512"},{"key":"2364_CR115","unstructured":"Akamatsu H, Sakata S, Azuma K, Yoshioka H, Uemura T, Tsuchiya-Kawano Y, et al. A single-arm, phase II study of sotorasib plus carboplatin\/pemetrexed in advanced non-squamous non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L, SCARLET). J thoracic oncol: official publication of the International Association for the Study of Lung Cancer.\u00a0J Thorac Oncol. 2025;S1556-0864(25)00007-3.\u00a0"},{"key":"2364_CR116","doi-asserted-by":"crossref","unstructured":"Yoshioka, H.; Akamatsu, H.; Sakata, S.; Azuma, K.; Uemura, T.; Tsuchiya-Kawano, Y.; Osuga, M.; Koh, Y.; Morita, S.; Yamamoto, N., Final analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer KRAS G12C mutation. J Clin Oncol.\u00a02024, 42 (16_suppl), 8616\u20138616.","DOI":"10.1200\/JCO.2024.42.16_suppl.8616"},{"key":"2364_CR117","doi-asserted-by":"crossref","unstructured":"Siena, S.; Yamaguchi, K.; Ruffinelli Rodriguez, J. C.; Corral de la Fuente, E.; Kuboki, Y.; Cremolini, C.; Victoria Ruiz, I.; Elez Fernandez, M. E.; Strickler, J. H.; Furqan, M.; Bashir, B.; Nduka, C.; Hippenmeyer, J.; Chan, E.; Xia, C.; Masuishi, T., 505O Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C&#x2013;mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study. Ann Oncol.\u00a02024, 35, S429-S430.","DOI":"10.1016\/j.annonc.2024.08.574"},{"issue":"18","key":"2364_CR118","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1158\/0008-5472.CAN-23-1313","volume":"83","author":"KCM Gulay","year":"2023","unstructured":"Gulay KCM, Zhang X, Pantazopoulou V, Patel J, Esparza E, Pran Babu DS, Ogawa S, Weitz J, Ng I, Mose ES, Pu M, Engle DD, Lowy AM, Tiriac H. Dual Inhibition of KRASG12D and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma. Cancer Res. 2023;83(18):3001\u201312.","journal-title":"Cancer Res"},{"issue":"8","key":"2364_CR119","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"N Tanaka","year":"2021","unstructured":"Tanaka N, Lin JJ, Li C, Ryan MB, Zhang J, Kiedrowski LA, Michel AG, Syed MU, Fella KA, Sakhi M, Baiev I, Juric D, Gainor JF, Klempner SJ, Lennerz JK, Siravegna G, Bar-Peled L, Hata AN, Heist RS, Corcoran RB. Clinical Acquired Resistance to KRAS(G12C) Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation. Cancer Discov. 2021;11(8):1913\u201322.","journal-title":"Cancer Discov"},{"issue":"25","key":"2364_CR120","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, Johnson ML, Heist RS, Patil T, Riely GJ, Jacobson JO, Yang X, Persky NS, Root DE, Lowder KE, Feng H, Zhang SS, Haigis KM, Hung YP, Sholl LM, Wolpin BM, Wiese J, Christiansen J, Lee J, Schrock AB, Lim LP, Garg K, Li M, Engstrom LD, Waters L, Lawson JD, Olson P, Lito P, Ou SI, Christensen JG, Janne PA, Aguirre AJ. Acquired Resistance to KRAS(G12C) Inhibition in Cancer. N Engl J Med. 2021;384(25):2382\u201393.","journal-title":"N Engl J Med"},{"issue":"4","key":"2364_CR121","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal A, Li BT, O\u2019Reilly EM. Targeting KRAS in cancer. Nat Med. 2024;30(4):969\u201383.","journal-title":"Nat Med"},{"issue":"4","key":"2364_CR122","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41401-023-01194-4","volume":"45","author":"Y Chen","year":"2024","unstructured":"Chen Y, Liu QP, Xie H, Ding J. From bench to bedside: current development and emerging trend of KRAS-targeted therapy. Acta Pharmacol Sin. 2024;45(4):686\u2013703.","journal-title":"Acta Pharmacol Sin"},{"key":"2364_CR123","doi-asserted-by":"crossref","unstructured":"Wang, J.; Zhao, J.; Fang, J.; Yu, Y.; Chu, Q.; Li, X.; Chen, J.; Liu, Z.; Zhang, L.; Wu, L.; Zhuang, W.; Li, X.; Zhao, Y.; Xing, L.; Liu, L.; Bai, C.; Dong, X.; Song, Q.; Wan, R.; Fang, X., 1261P Efficacy of glecirasib in combination with JAB-3312 as a front-line treatment for patients with KRAS p.G12C mutated NSCLC with PD-L1 expression levels or co-mutations. Ann Oncol.\u00a02024, 35, S808.","DOI":"10.1016\/j.annonc.2024.08.1318"},{"key":"2364_CR124","doi-asserted-by":"crossref","unstructured":"Negrao, M. V.; Cassier, P. A.; Solomon, B.; Schuler, M.; Rohrberg, K.; Cresta, S.; Dooms, C.; Tan, D. S. W.; Loong, H. H. f.; Amatu, A.; Assmann, K. K.; Fairchild, L.; Sansregret, L.; Fan, L.; Farago, A. F.; Cho, B. C., MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors. J Thoracic Oncol. 2023, 18 (11), S117-S118.","DOI":"10.1016\/j.jtho.2023.09.151"},{"issue":"1","key":"2364_CR125","doi-asserted-by":"publisher","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","volume":"11","author":"S Hamarsheh","year":"2020","unstructured":"Hamarsheh S, Gross O, Brummer T, Zeiser R. Immune modulatory effects of oncogenic KRAS in cancer. Nat Commun. 2020;11(1):5439.","journal-title":"Nat Commun"},{"issue":"1","key":"2364_CR126","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1158\/0008-5472.CAN-17-2084","volume":"78","author":"P Dias Carvalho","year":"2018","unstructured":"Dias Carvalho P, Guimaraes CF, Cardoso AP, Mendonca S, Costa AM, Oliveira MJ, Velho S. KRAS Oncogenic Signaling Extends beyond Cancer Cells to Orchestrate the Microenvironment. Cancer Res. 2018;78(1):7\u201314.","journal-title":"Cancer Res"},{"issue":"4","key":"2364_CR127","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ccell.2019.02.008","volume":"35","author":"W Liao","year":"2019","unstructured":"Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring DJ, Chang Q, Zhang J, Maru DM, Maeda DY, Zebala JA, Kopetz S, Wang YA, DePinho RA. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019;35(4):559-572.e7.","journal-title":"Cancer Cell"},{"key":"2364_CR128","doi-asserted-by":"crossref","unstructured":"Mugarza, E.; van Maldegem, F.; Boumelha, J.; Moore, C.; Rana, S.; Llorian Sopena, M.; East, P.; Ambler, R.; Anastasiou, P.; Romero-Clavijo, P.; Valand, K.; Cole, M.; Molina-Arcas, M.; Downward, J., Therapeutic KRAS G12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci adv.\u00a02022, 8 (29), eabm8780.","DOI":"10.1126\/sciadv.abm8780"},{"key":"2364_CR129","doi-asserted-by":"crossref","unstructured":"Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G, Bar-Sagi D. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell. 2012;21(6):836\u201347.","DOI":"10.1016\/j.ccr.2012.04.024"},{"issue":"4","key":"2364_CR130","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/2326-6066.CIR-15-0241","volume":"4","author":"S Zdanov","year":"2016","unstructured":"Zdanov S, Mandapathil M, Abu Eid R, Adamson-Fadeyi S, Wilson W, Qian J, Carnie A, Tarasova N, Mkrtichyan M, Berzofsky JA, Whiteside TL, Khleif SN. Mutant KRAS Conversion of Conventional T Cells into Regulatory T Cells. Cancer Immunol Res. 2016;4(4):354\u201365.","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"2364_CR131","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"Coelho MA, de Carn\u00e9 Tr\u00e9cesson S, Rana S, Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E, Barnouin K, Snijders AP, Lai WS, Blackshear PJ, Downward J. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. Immunity. 2017;47(6):1083-1099.e6.","journal-title":"Immunity"},{"key":"2364_CR132","doi-asserted-by":"publisher","first-page":"S872","DOI":"10.1016\/j.annonc.2024.08.1449","volume":"35","author":"MC Garassino","year":"2024","unstructured":"Garassino MC, J\u00e4nne PA, Barlesi F, Spira AI, Mok TSK, Hochmair M, O\u2019Byrne KJ, Felip E, Kim SW, Cappuzzo F, Naidoo J, Safadi M, Wamil B, He J, Reck M. 1394TiP KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation. Ann Oncol. 2024;35:S872\u20133.","journal-title":"Ann Oncol"},{"key":"2364_CR133","doi-asserted-by":"crossref","unstructured":"Li, B. T.; Falchook, G. S.; Durm, G. A.; Burns, T. F.; Skoulidis, F.; Ramalingam, S. S.; Spira, A.; Bestvina, C. M.; Goldberg, S. B.; Veluswamy, R.; Iams, W. T.; Chiappori, A. A.; Lemech, C. R.; Meloni, A. R.; Ebiana, V.; Dai, T.; Gauto, D. M.; Varrieur, T. L.; Snyder, W. J.; Govindan, R., OA03.06 CodeBreaK 100\/101: First Report of Safety\/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC. J Thoracic Oncol. 2022, 17 (9, Supplement), S10-S11.","DOI":"10.1016\/j.jtho.2022.07.025"},{"key":"2364_CR134","doi-asserted-by":"crossref","unstructured":"Burns, T. F.; Dragnev, K. H.; Fujiwara, Y.; Murciano-Goroff, Y. R.; Lee, D. H.; Hollebecque, A.; Koyama, T.; Cassier, P. A.; Italiano, A.; Heist, R. S.; Han, J.-Y.; Deming, D. A.; Spira, A. I.; Sabari, J. K.; Chisamore, M. J.; Fink, A. A.; Chen, A.; Willard, M. D.; Oxnard, G. R.; Ammakkanavar, N. R., Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with <i>KRAS<\/i> G12C-mutant advanced NSCLC. J Clin Oncol.\u00a02024, 42 (16_suppl), 8510\u20138510.","DOI":"10.1200\/JCO.2024.42.16_suppl.8510"},{"issue":"1","key":"2364_CR135","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41421-024-00699-4","volume":"10","author":"J Yang","year":"2024","unstructured":"Yang J, Wang QL, Wang GN, Ye JC, Li ZQ, Wang JY, Liang ZH, Li SX, Sun C, Liao WT, Gao YJ, Wang J, Mao Y, Yu CJ, Feng GK, Zeng MS. A pan-KRAS degrader for the treatment of KRAS-mutant cancers. Cell Discov. 2024;10(1):70.","journal-title":"Cell Discov."},{"issue":"48","key":"2364_CR136","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1038\/s41388-024-03186-y","volume":"43","author":"M Whaby","year":"2024","unstructured":"Whaby M, Ketavarapu G, Koide A, Mazzei M, Mintoo M, Glasser E, Patel U, Nasarre C, Sale MJ, McCormick F, Koide S, O\u2019Bryan JP. Inhibition and degradation of NRAS with a pan-NRAS monobody. Oncogene. 2024;43(48):3489\u201397.","journal-title":"Oncogene"},{"issue":"6","key":"2364_CR137","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1158\/1538-7445.AM2024-1654","volume":"84","author":"H Sase","year":"2024","unstructured":"Sase H, Michisaka S, Tachibana Y, Hasegawa M, Fujii T, Takei K, Kanei T, Murao N, Kuramoto S, Shibahara N, Ohta A, Tanada M, Shiraishi T, Iikura H, Kitazawa T, Tanaka H. Anti-tumor activity of orally-available cyclic peptide LUNA18 through direct RAS inhibition in RAS-altered tumors. Cancer Res. 2024;84(6):1654.","journal-title":"Cancer Res."},{"issue":"6","key":"2364_CR138","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1158\/1538-7445.AM2024-1664","volume":"84","author":"S Michisaka","year":"2024","unstructured":"Michisaka S, Sase H, Tachibana Y, Hasegawa M, Fujii T, Kuramoto S, Shibahara N, Ohta A, Tanada M, Shiraishi T, Iikura H, Kitazawa T, Tanaka H. 1664: Combination of LUNA18, a novel RAS inhibitor, with KRAS G12C inhibitors augments anti-tumor activity via inhibition of MAPK pathway reactivation. Cancer Res. 2024;84(6):1664.","journal-title":"Cancer Res."},{"issue":"30","key":"2364_CR139","doi-asserted-by":"publisher","first-page":"16610","DOI":"10.1021\/jacs.3c03886","volume":"145","author":"M Tanada","year":"2023","unstructured":"Tanada M, Tamiya M, Matsuo A, Chiyoda A, Takano K, Ito T, Irie M, Kotake T, Takeyama R, Kawada H, Hayashi R, Ishikawa S, Nomura K, Furuichi N, Morita Y, Kage M, Hashimoto S, Nii K, Sase H, Ohara K, Ohta A, Kuramoto S, Nishimura Y, Iikura H, Shiraishi T. Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor. J Am Chem Soc. 2023;145(30):16610\u201320.","journal-title":"J Am Chem Soc"},{"issue":"44","key":"2364_CR140","doi-asserted-by":"publisher","first-page":"24035","DOI":"10.1021\/jacs.3c07145","volume":"145","author":"A Ohta","year":"2023","unstructured":"Ohta A, Tanada M, Shinohara S, Morita Y, Nakano K, Yamagishi Y, Takano R, Kariyuki S, Iida T, Matsuo A, Ozeki K, Emura T, Sakurai Y, Takano K, Higashida A, Kojima M, Muraoka T, Takeyama R, Kato T, Kimura K, Ogawa K, Ohara K, Tanaka S, Kikuchi Y, Hisada N, Hayashi R, Nishimura Y, Nomura K, Tachibana T, Irie M, Kawada H, Torizawa T, Murao N, Kotake T, Tanaka M, Ishikawa S, Miyake T, Tamiya M, Arai M, Chiyoda A, Akai S, Sase H, Kuramoto S, Ito T, Shiraishi T, Kojima T, Iikura H. Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets. J Am Chem Soc. 2023;145(44):24035\u201351.","journal-title":"J Am Chem Soc"},{"key":"2364_CR141","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ijpharm.2019.02.032","volume":"561","author":"A Tirella","year":"2019","unstructured":"Tirella A, Kloc-Muniak K, Good L, Ridden J, Ashford M, Puri S, Tirelli N. CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment. Int J Pharm. 2019;561:114\u201323.","journal-title":"Int J Pharm"},{"issue":"46","key":"2364_CR142","doi-asserted-by":"publisher","first-page":"4761","DOI":"10.18632\/oncotarget.27109","volume":"10","author":"MS Strand","year":"2019","unstructured":"Strand MS, Krasnick BA, Pan H, Zhang X, Bi Y, Brooks C, Wetzel C, Sankpal N, Fleming T, Goedegebuure SP, DeNardo DG, Gillanders WE, Hawkins WG, Wickline SA, Fields RC. Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles. Oncotarget. 2019;10(46):4761\u201375.","journal-title":"Oncotarget"},{"issue":"9","key":"2364_CR143","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11095-019-2665-9","volume":"36","author":"A Mehta","year":"2019","unstructured":"Mehta A, Dalle Vedove E, Isert L, Merkel OM. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles. Pharm Res. 2019;36(9):133.","journal-title":"Pharm Res"},{"issue":"23","key":"2364_CR144","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1158\/1078-0432.CCR-16-2186","volume":"23","author":"L Gu","year":"2017","unstructured":"Gu L, Deng ZJ, Roy S, Hammond PT. A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS\/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer. Clin Cancer Res. 2017;23(23):7312\u201323.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2364_CR145","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1158\/2159-8290.CD-13-0900","volume":"4","author":"TL Yuan","year":"2014","unstructured":"Yuan TL, Fellmann C, Lee CS, Ritchie CD, Thapar V, Lee LC, Hsu DJ, Grace D, Carver JO, Zuber J, Luo J, McCormick F, Lowe SW. Development of siRNA payloads to target KRAS-mutant cancer. Cancer Discov. 2014;4(10):1182\u201397.","journal-title":"Cancer Discov"},{"issue":"51","key":"2364_CR146","doi-asserted-by":"publisher","first-page":"20723","DOI":"10.1073\/pnas.1314307110","volume":"110","author":"E Zorde Khvalevsky","year":"2013","unstructured":"Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E, Giladi H, Rivkin L, Simerzin A, Eliakim R, Khalaileh A, Hubert A, Lahav M, Kopelman Y, Goldin E, Dancour A, Hants Y, Arbel-Alon S, Abramovitch R, Shemi A, Galun E. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(51):20723\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2364_CR147","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116878","volume":"279","author":"D Han","year":"2024","unstructured":"Han D, Li A, Zhu L, Zhuang C, Zhao Q, Zou Y. Peptide inhibitors targeting Ras and Ras-associated protein-protein interactions. Eur J Med Chem. 2024;279: 116878.","journal-title":"Eur J Med Chem"},{"issue":"26","key":"2364_CR148","doi-asserted-by":"publisher","first-page":"7602","DOI":"10.1002\/anie.201502763","volume":"54","author":"P Upadhyaya","year":"2015","unstructured":"Upadhyaya P, Qian Z, Selner NG, Clippinger SR, Wu Z, Briesewitz R, Pei D. Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides. Angew Chem Int Ed Engl. 2015;54(26):7602\u20136.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"10","key":"2364_CR149","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1021\/acscentsci.0c00514","volume":"6","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Gao R, Hu Q, Peacock H, Peacock DM, Dai S, Shokat KM, Suga H. GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf. ACS Cent Sci. 2020;6(10):1753\u201361.","journal-title":"ACS Cent Sci"},{"issue":"3","key":"2364_CR150","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bbrc.2017.01.147","volume":"484","author":"K Sakamoto","year":"2017","unstructured":"Sakamoto K, Kamada Y, Sameshima T, Yaguchi M, Niida A, Sasaki S, Miwa M, Ohkubo S, Sakamoto JI, Kamaura M, Cho N, Tani A. K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology. Biochem Biophys Res Commun. 2017;484(3):605\u201311.","journal-title":"Biochem Biophys Res Commun"},{"issue":"17","key":"2364_CR151","doi-asserted-by":"publisher","first-page":"13038","DOI":"10.1021\/acs.jmedchem.1c01130","volume":"64","author":"M Buyanova","year":"2021","unstructured":"Buyanova M, Cai S, Cooper J, Rhodes C, Salim H, Sahni A, Upadhyaya P, Yang R, Sarkar A, Li N, Wang QE, Pei D. Discovery of a Bicyclic Peptidyl Pan-Ras Inhibitor. J Med Chem. 2021;64(17):13038\u201353.","journal-title":"J Med Chem"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02364-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02364-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02364-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T20:04:00Z","timestamp":1758744240000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02364-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2364"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02364-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"229"}}